Article
Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.
Fundamental & clinical pharmacology - 1 Apr 2016
de Moraes Natália V, Lauretti Gabriela R, Coelho Eduardo B, Godoy Ana Leonor P C, Neves Daniel V, Lanchote Vera L
Abstract excerpt
The pharmacokinetics of tramadol is characterized by a large interindividual variability, which is partially attributed to polymorphic CYP2D6 metabolism. The contribution of CYP3A, CYP2B6, fraction unbound, and other potential covariates remains unknown. This study aimed to investigate the contribution of in vivo activities of cytochrome P450 (CYP) 2D6 and 3A as well as other potential covariates (CYP2B6 genotype...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.